Predictors of the Effect of Tolvaptan on the Prognosis of Cirrhosis

Objective Tolvaptan was first approved for use for cirrhosis in Japan in September 2013. The aim of the study was to examine the effect of tolvaptan, a vasopressin V2 receptor antagonist, on the prognosis of cirrhosis. Methods The effect of tolvaptan was evaluated in 26 patients with cirrhosis treat...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Intern Med
Päätekijät: Iwamoto, Takuya, Maeda, Masaki, Hisanaga, Takuro, Saeki, Issei, Fujisawa, Koichi, Matsumoto, Toshihiko, Hidaka, Isao, Ishikawa, Tsuyoshi, Takami, Taro, Sakaida, Isao
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: The Japanese Society of Internal Medicine 2016
Aiheet:
Original Article
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC5109555/
https://ncbi.nlm.nih.gov/pubmed/27746425
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia